Avidity Partners Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Avidity Partners Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,393,000	Closed	-$115M	–	100
2022 Q1	$115M	Buy	1,393,000 +586,600	+73%	+$60M	2.38%	15
2021 Q4	$118M	Sell	806,400 -256,000	-24%	-$39.7M	2.51%	10
2021 Q3	$188M	Buy	1,062,400 +309,400	+41%	+$49.8M	4.16%	3
2021 Q2	$122M	Buy	753,000 +277,300	+58%	+$44.5M	3.29%	6
2021 Q1	$81.5M	Buy	475,700 +95,700	+25%	+$18.9M	2.25%	11
2020 Q4	$83.5M	Buy	380,000 +105,000	+38%	+$22.7M	2.71%	10
2020 Q3	$45.7M	Buy	+275,000	New	+$37.6M	2.12%	17
2020 Q2	–	Sell	-295,000	Closed	-$22.7M	–	80
2020 Q1	$22.7M	Buy	295,000 +231,000	+361%	+$20.7M	3.13%	8
2019 Q4	$8.25M	Buy	+64,000	New	+$6.17M	5.2%	5

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Avidity Partners Management's MRTX Position: Q2 2022 in Review

Avidity Partners Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 1,393,000 shares — an estimated $115M sold.

Avidity Partners Management first reported a position in MRTX in Q4 2019 and held it in 9 quarters. The position peaked at $188M in Q3 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Avidity Partners Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Avidity Partners Management sold 1,393,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $115M.
Avidity Partners Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Avidity Partners Management's Mirati Therapeutics, Inc. Common Stock position peaked at $188M in Q3 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.